Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WIC Infant Formula Bidding Requirements To Encompass Soy-Based Products

This article was originally published in The Tan Sheet

Executive Summary

State WIC agencies awarding a "single solicitation" bid for milk-based infant formula must require any manufacturer who does not also produce a soy-based formula to subcontract for supply of a soy product, the Food & Nutrition Service says in an interim rule.

You may also be interested in...



Noncontract infant formula documentation would be required under WIC proposed rule.

WIC MEDICAL DOCUMENTATION FOR ALL NONCONTRACT FORMULAS by an authorized medical professional would be required under a proposed rule published by the Department of Agriculture Food and Nutrition Service in the July 16 Federal Register. The proposed rule "would include all noncontract formulas among those formulas requiring medical documentation whether or not they comply with the requirements of an iron-fortified infant formula" as defined in regulations. Noncontract formulas are those brands or types of infant formulas not included in a particular state's contract with an infant formula manufacturer issued under the Special Supplemental Nutrition Program for Women, Infants & Children.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel